DaShenLin Pharmaceutical Group Co., Ltd. (SHA:603233)

China · Delayed Price · Currency is CNY

18.22

-0.16 (-0.87%)

Sep 16, 2026, 3:00 PM CST

Market Cap	20.75B +5.4%
Revenue (ttm)	27.97B +4.9%
Net Income	1.36B +29.2%
EPS	1.19 +27.7%
Shares Out	1.14B
PE Ratio	15.31
Forward PE	14.16
Dividend	0.98 (5.29%)
Ex-Dividend Date	Jun 26, 2026

Volume	5,514,199
Open	18.32
Previous Close	18.38
Day's Range	18.04 - 18.44
52-Week Range	14.39 - 21.78
Beta	0.41
Analysts	Buy
Price Target	23.75 (+30.35%)
Earnings Date	Aug 25, 2026

About SHA:603233

DaShenLin Pharmaceutical Group Co., Ltd. engages in the manufacture, distribution, and retail of pharmaceutical products in China. It offers Chinese and Western patent medicines, ginseng and tonic herbs, Chinese herbal medicine slices, health products, medical devices, and other commodities. The company was incorporated in 1999 and is based in Guangzhou, China. [Read more]

Industry Pharmaceutical Retailers

Sector Healthcare

Founded 1999

Employees 41,141

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 603233

Full Company Profile

Financial Performance

In 2025, SHA:603233's revenue was 27.50 billion, an increase of 3.80% compared to the previous year's 26.50 billion. Earnings were 1.24 billion, an increase of 35.04%.

Financial Statements

Analyst Summary

According to 12 analysts, the average rating for 603233 stock is "Buy." The 12-month stock price target is ¥23.75, which is an increase of 30.35% from the latest price.

Price Target

¥23.75

(30.35% upside)

Analyst Consensus: Buy

Stock Forecasts